scholarly journals Our Experience With Photodynamic Diagnosis and Photodynamic Therapy for Lung Cancer

2012 ◽  
Vol 10 (Suppl_2) ◽  
pp. S-3-S-8 ◽  
Author(s):  
Harubumi Kato
Keyword(s):  
Lung Cancer ◽  
Optical Coherence Tomography ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Lung Tumors ◽  
Photodynamic Diagnosis ◽  
Light Sources ◽  
Fiberoptic Bronchoscope ◽  
Lung Cancers ◽  
Diagnosis Of Lung Cancer

The diagnosis of lung cancer was significantly enhanced by the development of the fiberoptic bronchoscope in 1965. Since then, advances in photosensitizers and light sources have brought photodynamic medicine into the light. This article offers an historic overview of the emergence of photodynamic medicine through the perspective of a pioneer with more than 30 years’ experience. Along with a discussion of photodynamic diagnosis of lung cancers via optical coherence tomography, the curative, palliative, and neoadjuvant roles of photodynamic therapy for early and advanced lung cancers are explored. An emerging strategy of using PDM to treat peripheral early-stage lung tumors is briefly discussed.

scholarly journals Photodynamic Therapy With YAG-OPO Laser for Early Stage Lung Cancer

1997 ◽  
Vol 4 (2) ◽  
pp. 75-81 ◽  
Author(s):  
Harubumi Kato ◽  
Tetsuya Okunaka ◽  
Chimori Konaka ◽  
Kiyoyuki Furuse ◽  
Yoko Kusunoki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Complete Remission ◽  
Early Stage ◽  
Tunable Laser ◽  
Dye Laser ◽  
Early Stage Lung Cancer ◽  
Lung Cancers ◽  
Stage Lung Cancer ◽  
Argon Dye Laser

Photodynamic therapy (PDT) utilizing Photofrin is proving to be effective for the treatment of early stage lung cancers. The effect of PDT utilizing YAG-OPO laser as new light source was evaluated in 26 patients (29 lesions) with early stage lung cancers. YAG-OPO laser is solid state tunable laser which is easy to change wavelength between 620 and 670 nm exciting various kinds of photosensitizers. Moreover, YAG-OPO laser is more reliable, smaller and has less consumables than argon-dye laser or excimer-dye laser. As the result of PDT with YAG-OPO laser, complete remission (CR) was obtained in 82.6% of the 29 lesions, partial remission (PR) in 13.8% and no change (NC) was obtained in 3.4%. We conclude that PDT utilizing YAG-OPO laser is efficacious in the treatment of early stage lung cancers and can achieve complete remission.

scholarly journals Photodynamic Therapy of Lung Cancer With Bronchial Artery Infusion of Photofrin

1996 ◽  
Vol 2 (4) ◽  
pp. 203-206 ◽  
Author(s):  
Tetsuya Okunaka ◽  
Harubumi Kato ◽  
Chimori Konaka ◽  
Kinya Furukawa ◽  
Masahiko Harada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Bronchial Artery ◽  
Arterial Infusion ◽  
Early Stage Lung Cancer ◽  
Hospitalization Period ◽  
Bronchial Arterial Infusion ◽  
Skin Photosensitivity ◽  
Stage Lung Cancer

Photodynamic therapy (PDT) utilizing Photofrin is proving to be effective for the treatment of early stage lung cancer. However, wider clinical applications of Photofrin as a photosensitizer for various cancers are hampered by potentially serious and prolonged skin photosensitivity. To prevent these side effects and reduce the hospitalization period, we recently gave reduced doses of Photofrin by bronchial arterial infusion. Five patients with endoscopically evaluated minimally invasive carcinoma of the lung were given 0.7 mg/kg of Photofrin by bronchial arterial infusion 48 hr before PDT. Complete remission was obtained in all 5 cases and no case showed skin photosensitivity when exposed to sunlight under careful surveillance at one week after PDT.

scholarly journals Reducing False-Positives in Lung Nodules Detection Using Balanced Datasets

2021 ◽  
Vol 9 ◽  
Author(s):  
Jinglun Liang ◽  
Guoliang Ye ◽  
Jianwen Guo ◽  
Qifan Huang ◽  
Shaohui Zhang
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Pulmonary Nodules ◽  
Ct Images ◽  
False Positives ◽  
Classification Systems ◽  
Cad System ◽  
Nodule Detection ◽  
Diagnosis Of Lung Cancer ◽  
Lung Ct

Malignant pulmonary nodules are one of the main manifestations of lung cancer in early CT image screening. Since lung cancer may have no early obvious symptoms, it is important to develop a computer-aided detection (CAD) system to assist doctors to detect the malignant pulmonary nodules in the early stage of lung cancer CT diagnosis. Due to the recent successful applications of deep learning in image processing, more and more researchers have been trying to apply it to the diagnosis of pulmonary nodules. However, due to the ratio of nodules and non-nodules samples used in the training and testing datasets usually being different from the practical ratio of lung cancer, the CAD classification systems may easily produce higher false-positives while using this imbalanced dataset. This work introduces a filtering step to remove the irrelevant images from the dataset, and the results show that the false-positives can be reduced and the accuracy can be above 98%. There are two steps in nodule detection. Firstly, the images with pulmonary nodules are screened from the whole lung CT images of the patients. Secondly, the exact locations of pulmonary nodules will be detected using Faster R-CNN. Final results show that this method can effectively detect the pulmonary nodules in the CT images and hence potentially assist doctors in the early diagnosis of lung cancer.

An Automated Computer System Based on Genetic Algorithm and Fuzzy Systems for Lung Cancer Diagnosis

2018 ◽  
Vol 19 (6) ◽  
pp. 583-594 ◽  
Author(s):  
Abir Alharbi
Keyword(s):  
Lung Cancer ◽  
Real Data ◽  
Classification Performance ◽  
Automated System ◽  
Lung Cancers ◽  
Cancer Data ◽  
Lung Cancer Diagnosis ◽  
Degree Of Confidence ◽  
Diagnosis Of Lung Cancer ◽  
Rule System

AbstractAn automated system for the diagnosis of lung cancer is proposed in this paper, the system is designed by combining two major methodologies, namely the fuzzy base systems and the evolutionary genetic algorithms (GAs), to be employed on lung cancer data to assist physicians in the early detection of lung cancers, and hence obtain an early automated diagnosis complementary to that by physicians. Our hybrid algorithm, the genetic-fuzzy algorithm, has produced optimized diagnosis systems that attain high classification performance, in fact, our best six rule system obtained a 97.5 % accuracy, with simple and well interpretive rules, with 93 % degree of confidence, and without the need for dimensionality reduction. The results on real data indicate that the proposed system is very effective in the diagnosis of lung cancer and can be used for clinical applications.

Does multiplicity of synchronous multiple lung primaries (SMLPs) affect prognosis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20530-e20530
Author(s):  
RuoBing Xue ◽  
Satish Maharaj ◽  
Rohit Kumar ◽  
Goetz H. Kloecker
Keyword(s):  
Lung Cancer ◽  
Adjuvant Therapy ◽  
Early Stage ◽  
Primary Lung Cancer ◽  
Case Series ◽  
Current Recommendation ◽  
Lung Cancers ◽  
T Stage ◽  
Wide Range ◽  
Common Risk Factors

e20530 Background: SMLPs are detected more commonly due to advancements in screening technology. Their workup and classification; however, are still lacking a clear standard. T stage of the largest lesion has been used as the major prognostic marker. This; however, does not take the number of SMLPs and their genomic drivers into consideration. This study aims to identify and review common risk factors associated with SMLPs and determine whether the number of primaries influence the prognosis. Methods: A systematic review of the literature published between 2000 and 2021 was conducted through PubMed and Medline by using the combination of keywords, including: “synchronous multiple primary lung cancer”, “simultaneous multifocal lung cancer”, “synchronous solitary lung metastasis”, “risk factor” and “prognosis”. A total of fifty studies were identified, among them only sixteen retrospective research articles and two review articles were relevant to the study at hand. Results: Sixteen retrospective studies including a total of 1685 eligible patients were reviewed. Thirteen of these studies reported the main histology type to be adenocarcinoma with a ratio ranging from 35% to 96.8%. Eight studies have reported the numbers of synchronous primary lung cancers, including one study found 11 SMLPs. Among these, one study by van Rens found number of SMLPs impact prognosis adversely compared to a single lung cancer. However, three other studies demonstrated multiple SMPLs do not adversely affect survival (Finley et al, 2010; Kocaturk et al, 2011; Li et al, 2020). Four of the sixteen studies analysed the effect of multiple lobes involvement and distance between tumors, with varying conclusions; two studies reported no difference in prognosis while one study revealed worse survival with multiple lobe involvement and one study found favorable outcome. Most studies confirm the usual prognostic factors for SMLPs, including: gender, smoking, type of surgery, comorbidities and adjuvant therapy. The median 5 year OS reported for SMLPs is 66%, with a wide range from 19% to 95.8%.The 3 year OS is 75% in most studies. Conclusions: The data on how the number of SMLPs affects the prognosis is uncertain. The current recommendation to base the decision for adjuvant therapy on the highest T stage is not supported by prospective evidence or consistent among published case series. Considering the recent approval of targeted therapies in early stage lung cancers, a better prognostic scoring system for SMLPs is required.

Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-stage Lung Cancer Diagnosis

2020 ◽  
Author(s):  
Lingling Wan ◽  
Yutong He ◽  
Qingyi Liu ◽  
Di Liang ◽  
Yongdong Guo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Early Stage ◽  
Untargeted Metabolomics ◽  
Early Stage Lung Cancer ◽  
Lung Cancer Patients ◽  
Diagnosis Of Lung Cancer ◽  
Metabolomics Analysis ◽  
Stage Lung Cancer

Abstract Background: Lung cancer is a malignant tumor that has the highest morbidity and mortality rate among all cancers. Early diagnosis of lung cancer is a key factor in reducing mortality and improving prognosis. Methods: In this study, we performed CTC next-generation sequencing (NGS) in early-stage lung cancer patients to identify lung cancer-related gene mutations. Meanwhile, a serum liquid chromatography-tandem mass spectrometry (LC-MS) untargeted metabolomics analysis was performed in the CTC-positive patients, and the early diagnostic value of these assays in lung cancer was analyzed. Results: 62.5% (30/48) of lung cancer patients had ≥ 1 CTC. By CTC NGS, we found that > 50% of patients had 4 commonly mutated genes, namely, NOTCH1, IGF2, EGFR, and PTCH1. 47.37% (9/19) patients had ARIDH1 mutations. Additionally, 30 CTC-positive patients and 30 healthy volunteers were subjected to LC-MS untargeted metabolomics analysis. We found 100 different metabolites, and 10 different metabolites were identified through analysis, which may have potential clinical application value in the diagnosis of CTC-positive early-stage lung cancer (AUC > 0.9). Conclusions: Our results indicate that NGS of CTC and metabolomics may provide new tumor markers for the early diagnosis of lung cancer. This possibility requires more in-depth large-sample research for verification.

Newer procedures using the fiberoptic bronchoscope in the diagnosis of lung cancer

1987 ◽  
Vol 54 (3) ◽  
pp. 195-203 ◽  
Author(s):  
A. C. Mehta ◽  
M. Ahmad ◽  
C. Nunez ◽  
J. A. Golish
Keyword(s):  
Lung Cancer ◽  
Fiberoptic Bronchoscope ◽  
Diagnosis Of Lung Cancer

Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy

Lung Cancer ◽  
2007 ◽  
Vol 58 (3) ◽  
pp. 317-323 ◽  
Author(s):  
Jitsuo Usuda ◽  
Hidemitsu Tsutsui ◽  
Hidetoshi Honda ◽  
Shuji Ichinose ◽  
Taichirou Ishizumi ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Photodynamic Diagnosis ◽  
Lung Cancers ◽  
Talaporfin Sodium ◽  
Autofluorescence Bronchoscopy

External validation of a panel of plasma microRNA biomarkers for lung cancer

2019 ◽  
Vol 13 (18) ◽  
pp. 1557-1564 ◽  
Author(s):  
Jin Li ◽  
HongBin Fang ◽  
Fang Jiang ◽  
Yang Ning
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
External Validation ◽  
Early Stage Lung Cancer ◽  
Combined Use ◽  
Diagnostic Values ◽  
Plasma Microrna ◽  
Diagnosis Of Lung Cancer ◽  
Lung Cancer Detection ◽  
Plasma Mirnas

Aim: We externally validate plasma miRNAs biomarkers for lung cancer in a large and retrospective sample set collected from a geographically distant population. Methods: Plasma samples are tested blindly to the clinical annotations by using PCR for quantitation of the four miRNAs in cohort 1 consisting of 232 lung cancer cases and 243 controls and cohort 2 comprising 239 cases and 246 controls. Results: Combined use of the four plasma miRNAs has 91% sensitivity and 95% specificity for diagnosis of lung cancer, and 85% sensitivity for early-stage lung cancer, while maintaining a specificity of 95%. Conclusion: The diagnostic values of the biomarkers are reproducibly confirmed in the independent and large sample sets, providing an assay for lung cancer detection.

Sign in / Sign up

Export Citation Format

Share Document